In the news

Kyra Williams shares her experience with endoscopic sleeve gastroplasty, a minimally invasive weight loss procedure that helped support her goals.

AI adoption is much bigger than a workplace tech initiative – it’s a change management challenge. That’s why, writes SVP of enterprise services and digital officer Jodi Euerle Eddy, “if your IT department aims to create an AI-enabled workforce, a close IT and HR partnership is essential.”

Read how the AGENT™ Drug Coated Balloon — now available in the U.S. — addresses a critical unmet need for in-stent restenosis (ISR) treatment, using tech that represents a “quantum leap” forward.

A recent survey highlights that women are seeking new ways to lose weight, as Boston Scientific launches Endura Weight Loss Solutions to increase awareness of minimally invasive weight loss procedures.

Ronald Morton, M.D., chief medical officer, Urology, Boston Scientific sheds light on two taboo topics affecting millions of men: erectile dysfunction (ED) and stress urinary incontinence (SUI).

At STAT’s AI-focused Breakthrough Summit West, Ken Stein, MD, senior vice president and global chief medical officer, shares how artificial intelligence is helping cardiologists make the leap from available insights to actionable ones.

At DeviceTalks Minnesota, Ken Stein, MD, senior vice president and global chief medical officer, outlines the steps Boston Scientific takes to evaluate a market, choose a development approach and establish the groundwork for adoption.

CEO Mike Mahoney shares lessons learned over his career that helped him shape Boston Scientific's winning culture and drive the company’s growth.

Lisa Considine, senior vice president of global talent, describes the professional development opportunities offered by Boston Scientific to early career talent that supports the company’s top ranking on Forbes’ list of America’s Best Employers for New Grads.

Dr. Michael R. Jaff, chief medical officer, Peripheral Interventions, discusses new data supporting the Eluvia™ Drug-Eluting Vascular Stent System presented at the Charing Cross Symposium. The article also explores how design elements of the device contribute to long-term outcomes in treating peripheral artery disease and future opportunities for innovation in drug-device combination therapies.